{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:44:19Z","timestamp":1792079059215,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7280","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/nature08675","type":"journal-article","created":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T16:39:23Z","timestamp":1263400763000},"page":"501-506","source":"Crossref","is-referenced-by-count":573,"title":["Targeting Bcr\u2013Abl by combining allosteric with ATP-binding-site inhibitors"],"prefix":"10.1038","volume":"463","author":[{"given":"Jianming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Adri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Jahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra W.","family":"Cowan-Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana E.","family":"Iacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taebo","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barun","family":"Okram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Fendrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navratna","family":"Vajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grzesiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Tuntland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badry","family":"Bursulaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Engen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Q.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Warmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,13]]},"reference":[{"key":"BFnature08675_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129\u2013141 (2005)","journal-title":"Cancer Cell"},{"key":"BFnature08675_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nature Rev. Drug Discov. 6, 834\u2013848 (2007)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature08675_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399\u2013401 (2004)","journal-title":"Science"},{"key":"BFnature08675_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001)","journal-title":"Science"},{"key":"BFnature08675_CR5","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236\u20134243 (2002)","journal-title":"Cancer Res."},{"key":"BFnature08675_CR6","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen, H. A. et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332\u20132338 (2006)","journal-title":"Blood"},{"key":"BFnature08675_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adrian","year":"2006","unstructured":"Adrian, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nature Chem. Biol. 2, 95\u2013102 (2006)","journal-title":"Nature Chem. Biol."},{"key":"BFnature08675_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00018-003-3382-3","volume":"61","author":"W Jahnke","year":"2004","unstructured":"Jahnke, W. & Widmer, H. Protein NMR in biomedical research. Cell. Mol. Life Sci. 61, 580\u2013599 (2004)","journal-title":"Cell. Mol. Life Sci."},{"key":"BFnature08675_CR9","doi-asserted-by":"publisher","first-page":"18292","DOI":"10.1074\/jbc.M801337200","volume":"283","author":"N Vajpai","year":"2008","unstructured":"Vajpai, N. et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib. J. Biol. Chem. 283, 18292\u201318302 (2008)","journal-title":"J. Biol. Chem."},{"key":"BFnature08675_CR10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859\u2013871 (2003)","journal-title":"Cell"},{"key":"BFnature08675_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel, O. et al. A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell 112, 845\u2013857 (2003)","journal-title":"Cell"},{"key":"BFnature08675_CR12","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray, A. et al. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109, 5011\u20135015 (2007)","journal-title":"Blood"},{"key":"BFnature08675_CR13","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2004-06-2445","volume":"105","author":"N von Bubnoff","year":"2005","unstructured":"von Bubnoff, N. et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105, 1652\u20131659 (2005)","journal-title":"Blood"},{"key":"BFnature08675_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831\u2013843 (2003)","journal-title":"Cell"},{"key":"BFnature08675_CR15","doi-asserted-by":"publisher","first-page":"9244","DOI":"10.1073\/pnas.0600001103","volume":"103","author":"M Azam","year":"2006","unstructured":"Azam, M. et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR\/ABL kinase dynamics in drug resistance. Proc. Natl Acad. Sci. USA 103, 9244\u20139249 (2006)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature08675_CR16","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472\u20133475 (2002)","journal-title":"Blood"},{"key":"BFnature08675_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117\u2013125 (2002)","journal-title":"Cancer Cell"},{"key":"BFnature08675_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984)","journal-title":"Adv. Enzyme Regul."},{"key":"BFnature08675_CR19","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1158\/0008-5472.CAN-05-3058","volume":"66","author":"S Mishra","year":"2006","unstructured":"Mishra, S. et al. Resistance to imatinib of bcr\/abl p190 lymphoblastic leukemia cells. Cancer Res. 66, 5387\u20135393 (2006)","journal-title":"Cancer Res."},{"key":"BFnature08675_CR20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9258(18)56102-0","volume":"189","author":"A Kornberg","year":"1951","unstructured":"Kornberg, A. & Pricer, W. E. Di- and triphosphopyridine nucleotide isocitric dehydrogenases in yeast. J. Biol. Chem. 189, 123\u2013136 (1951)","journal-title":"J. Biol. Chem."},{"key":"BFnature08675_CR21","doi-asserted-by":"publisher","first-page":"29005","DOI":"10.1074\/jbc.M109.026633","volume":"284","author":"Y Choi","year":"2009","unstructured":"Choi, Y. et al. N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor. J. Biol. Chem. 284, 29005\u201329014 (2009)","journal-title":"J. Biol. Chem."},{"key":"BFnature08675_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/mas.20064","volume":"25","author":"TE Wales","year":"2006","unstructured":"Wales, T. E. & Engen, J. R. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25, 158\u2013170 (2006)","journal-title":"Mass Spectrom. Rev."},{"key":"BFnature08675_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1073\/pnas.0811912106","volume":"106","author":"RE Iacob","year":"2009","unstructured":"Iacob, R. E. et al. Conformational disturbance in Abl kinase upon mutation and deregulation. Proc. Natl Acad. Sci. USA 106, 1386\u20131391 (2009)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature08675_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/10428199309047893","volume":"11","author":"RA van Etten","year":"1993","unstructured":"van Etten, R. A. Disease progression in a murine model of bcr\/abl leukemogenesis. Leuk. Lymphoma 11 (suppl. 1). 239\u2013242 (1993)","journal-title":"Leuk. Lymphoma"},{"key":"BFnature08675_CR25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","volume":"344","author":"H Joensuu","year":"2001","unstructured":"Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052\u20131056 (2001)","journal-title":"N. Engl. J. Med."},{"key":"BFnature08675_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004)","journal-title":"N. Engl. J. Med."},{"key":"BFnature08675_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005)","journal-title":"N. Engl. J. Med."},{"key":"BFnature08675_CR28","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1158\/0008-5472.CAN-04-2148","volume":"64","author":"J Cools","year":"2004","unstructured":"Cools, J. et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 64, 6385\u20136389 (2004)","journal-title":"Cancer Res."},{"key":"BFnature08675_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.chembiol.2004.02.029","volume":"11","author":"S Blencke","year":"2004","unstructured":"Blencke, S. et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691\u2013701 (2004)","journal-title":"Chem. Biol."},{"key":"BFnature08675_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756\u2013758 (1994)","journal-title":"Nature"},{"key":"BFnature08675_CR31","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.1073\/pnas.92.17.7686","volume":"92","author":"DT Dudley","year":"1995","unstructured":"Dudley, D. T. et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92, 7686\u20137689 (1995)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature08675_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1042\/BJ20041140","volume":"385","author":"SF Barnett","year":"2005","unstructured":"Barnett, S. F. et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399\u2013408 (2005)","journal-title":"Biochem. J."},{"key":"BFnature08675_CR33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1074\/jbc.M209677200","volume":"278","author":"JR Burke","year":"2003","unstructured":"Burke, J. R. et al. BMS-345541 is a highly selective inhibitor of I\u03baB kinase that binds at an allosteric site of the enzyme and blocks NF-\u03baB-dependent transcription in mice. J. Biol. Chem. 278, 1450\u20131456 (2003)","journal-title":"J. Biol. Chem."},{"key":"BFnature08675_CR34","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.bmcl.2008.12.076","volume":"19","author":"A Converso","year":"2009","unstructured":"Converso, A. et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett. 19, 1240\u20131244 (2009)","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnature08675_CR35","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1016\/S0021-9258(19)39565-1","volume":"265","author":"H Tokumitsu","year":"1990","unstructured":"Tokumitsu, H. et al. KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine, a specific inhibitor of Ca2+\/calmodulin-dependent protein kinase II. J. Biol. Chem. 265, 4315\u20134320 (1990)","journal-title":"J. Biol. Chem."},{"key":"BFnature08675_CR36","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/cncr.23355","volume":"112","author":"TS Lee","year":"2008","unstructured":"Lee, T. S. et al. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 112, 1744\u20131753 (2008)","journal-title":"Cancer"},{"key":"BFnature08675_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10858-005-2451-3","volume":"31","author":"A Strauss","year":"2005","unstructured":"Strauss, A. et al. Efficient uniform isotope labeling of Abl kinase expressed in Baculovirus-infected insect cells. J. Biomol. NMR 31, 343\u2013349 (2005)","journal-title":"J. Biomol. NMR"},{"key":"BFnature08675_CR38","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1110\/ps.051750905","volume":"14","author":"MA Seeliger","year":"2005","unstructured":"Seeliger, M. A. et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14, 3135\u20133139 (2005)","journal-title":"Protein Sci."},{"key":"BFnature08675_CR39","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1073\/pnas.84.23.8200","volume":"84","author":"C Oppi","year":"1987","unstructured":"Oppi, C., Shore, S. K. & Reddy, E. P. Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation. Proc. Natl Acad. Sci. USA 84, 8200\u20138204 (1987)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature08675_CR40","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1021\/ac8008862","volume":"80","author":"TE Wales","year":"2008","unstructured":"Wales, T. E., Fadgen, K. E., Gerhardt, G. C. & Engen, J. R. High-speed and high-resolution UPLC separation at zero degrees Celsius. Anal. Chem. 80, 6815\u20136820 (2008)","journal-title":"Anal. Chem."},{"key":"BFnature08675_CR41","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jasms.2006.07.025","volume":"17","author":"DD Weis","year":"2006","unstructured":"Weis, D. D., Engen, J. R. & Kass, I. J. Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J. Am. Soc. Mass Spectrom. 17, 1700\u20131703 (2006)","journal-title":"J. Am. Soc. Mass Spectrom."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature08675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature08675","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature08675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:30:26Z","timestamp":1684434626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature08675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":41,"journal-issue":{"issue":"7280","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["BFnature08675"],"URL":"https:\/\/doi.org\/10.1038\/nature08675","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}